208 related articles for article (PubMed ID: 30589629)
1. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
Stanford RH; Lau MS; Li Y; Stemkowski S
J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a drug adherence index for COPD.
Bengtson LGS; Bancroft T; Schilling C; Buikema AR; Stanford RH
J Manag Care Spec Pharm; 2021 Feb; 27(2):198-209. PubMed ID: 33506734
[No Abstract] [Full Text] [Related]
3. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
[TBL] [Abstract][Full Text] [Related]
4. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
Lane DC; Stemkowski S; Stanford RH; Tao Z
J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
[TBL] [Abstract][Full Text] [Related]
5. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
Palli SR; Zhou S; Shaikh A; Willey VJ
J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
[No Abstract] [Full Text] [Related]
6. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
Tran M; Xiang P; Rascati KL; Stock EM; Godley PJ; Coleman A; Bogart MR; Stanford RH
J Manag Care Spec Pharm; 2016 Oct; 22(10):1186-93. PubMed ID: 27668567
[TBL] [Abstract][Full Text] [Related]
7. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
8. Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations.
Stanford RH; Korrer S; Brekke L; Reinsch T; Bengtson LGS
Chronic Obstr Pulm Dis; 2020 Jan; 7(1):38-48. PubMed ID: 31999901
[TBL] [Abstract][Full Text] [Related]
9. Claims-based risk model for first severe COPD exacerbation.
Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Schatz M; Vekeman F; Gauthier-Loiselle M; Merrigan JFP; Duh MS
Am J Manag Care; 2018 Feb; 24(2):e45-e53. PubMed ID: 29461849
[TBL] [Abstract][Full Text] [Related]
10. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
11. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
12. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
[TBL] [Abstract][Full Text] [Related]
13. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
14. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
16. COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members.
Pasquale MK; Xu Y; Baker CL; Zou KH; Teeter JG; Renda AM; Davis CC; Lee TC; Bobula J
Int J Chron Obstruct Pulmon Dis; 2016; 11():111-21. PubMed ID: 26834468
[TBL] [Abstract][Full Text] [Related]
17. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.
Dalal AA; Shah MB; D'Souza AO; Lunacsek OE; Nagar SP; Crater GD
Respir Res; 2012 May; 13(1):41. PubMed ID: 22651541
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data.
Annavarapu S; Goldfarb S; Gelb M; Moretz C; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2018; 13():2121-2130. PubMed ID: 30022818
[TBL] [Abstract][Full Text] [Related]
19. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
Abudagga A; Sun SX; Tan H; Solem CT
Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
[TBL] [Abstract][Full Text] [Related]
20. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
